Welcome to our dedicated page for IRIDEX SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IRIDEX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IRIDEX's regulatory disclosures and financial reporting.
Iridex Corp director William M. Moore received two stock option grants on June 13, 2025, as reported in this Form 4 filing:
- First grant: 53,000 stock options with exercise price of $0.94, vesting fully on either the one-year anniversary or 2026 annual meeting
- Second grant: 15,000 stock options with exercise price of $0.94, vesting monthly over four years starting July 13, 2025
Both options were granted under the company's 2008 Equity Incentive Plan and expire on June 13, 2032. The grants are exempt under Rule 16b-3. This compensation structure aligns the director's interests with shareholders through both short-term and long-term vesting schedules. The low exercise price suggests the stock may be trading near historical lows.
Iridex Corp CFO Romeo R. Dizon filed an amended Form 4 reporting two significant equity transactions on June 13, 2025:
- Acquired 22,500 Restricted Stock Units (RSUs) at $0.94 per share, with vesting over three years starting June 13, 2026 (one-third annually)
- Received stock options to purchase 75,000 shares of common stock at an exercise price of $0.94, vesting over three years and expiring June 13, 2032
Following these transactions, Dizon directly owns 37,745 shares and 75,000 stock options. This amended filing corrects a previous Form 4 filed on June 17, 2025. The equity awards were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. These grants appear to be part of executive compensation arrangements, demonstrating long-term alignment with shareholder interests through multi-year vesting schedules.
This Form 4/A amendment reports insider trading activity for Patrick Mercer, President and CEO of Iridex Corp (IRIX), correcting a filing from June 17, 2025. The transactions occurred on June 13, 2025 and include two key components:
- Restricted Stock Units (RSUs): Acquired 33,370 RSUs at $0.94 per share. These RSUs vest over three years, with one-third vesting annually starting June 13, 2026, contingent on continued service
- Stock Options: Granted rights to purchase 111,240 shares of common stock at an exercise price of $0.94 per share. These options vest over three years (one-third annually) and expire on June 13, 2032
Following these transactions, Mercer directly owns 420,100 shares. The equity awards were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. This compensation structure aligns the CEO's interests with long-term shareholder value through significant equity ownership requirements and performance incentives.